Hydrogenology
Hydrogenology editorial study record

Consumption of water containing a high concentration of molecular hydrogen reduces oxidative stress and disease activity in patients with rheumatoid arthritis: an open-label pilot study

Ishibashi T et al. · Med Gas Res. 2012;2(1):27.

HumanH₂-rich waterPublished 2012
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Open-label uncontrolled pilot with two treatment periods

Research topic

Immune and inflammatory conditions

Administration classification

H₂-rich water

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Adults with rheumatoid arthritis continuing their usual therapy

Sample

20 participants

Duration

Two 4-week treatment periods separated by a 4-week washout

Intervention

530 mL/day high-H₂ water for 4 weeks, followed by 4 weeks without it, then another 4-week treatment period

Hydrogen form

H₂ dissolved in water — H₂ only, not Brown’s gas.

H₂ specification

4–5 ppm dissolved H₂ at preparation, described as supersaturated water.

H₂ flow

Not applicable — oral water, not gas inhalation.

O₂ delivered with H₂

No O₂ was co-delivered as part of the intervention.

Comparator

No placebo or concurrent untreated comparator

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Urinary 8-OHdG and rheumatoid-arthritis disease activity score DAS28-CRP

Reported result

8-OHdG and DAS28 decreased during treatment, but mean DAS28 also continued to decrease during the washout period. The report emphasizes a five-person early-RA subgroup.

Results-extraction completeness

Methods and main results checked in the free full text; independent appraisal and complete commercial-support extraction remain incomplete.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Open-label, uncontrolled 20-person pilot; ongoing usual therapy, regression to the mean and the continued improvement during washout make causal attribution uncertain. The five-person subgroup is especially fragile.

Applies directly to

Adults with rheumatoid arthritis under continued background care in this pilot.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 23031079 · DOI: 10.1186/2045-9912-2-27

Publisher access

Open-access article.

Extraction basis

Free full text on PMC; identifiers cross-checked in PubMed.

Record revision

2026-08-10